Last reviewed · How we verify
Etrasimod Immediate Release (IR) (etrasimod-immediate-release-ir)
Etrasimod Immediate Release (IR) (generic name: etrasimod-immediate-release-ir) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
Etrasimod Immediate Release (IR) is being studied in a clinical trial involving healthy participants. The purpose of this study is to evaluate the use of wearable sensors with the study medication (etrasmiod) in healthy participants.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | etrasimod-immediate-release-ir |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Application site irritation
- Atrioventricular block first degree
- Vessel puncture site haematoma
- Lip dry
- Puncture site erythema
- Headache
- Puncture site injury
- Vision blurred
- Nausea
- Fatigue
- Influenza like illness
- Post procedural haematoma
Key clinical trials
- A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants (PHASE1)
- A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etrasimod Immediate Release (IR) CI brief — competitive landscape report
- Etrasimod Immediate Release (IR) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Etrasimod Immediate Release (IR)
What is Etrasimod Immediate Release (IR)?
Who makes Etrasimod Immediate Release (IR)?
What is the generic name of Etrasimod Immediate Release (IR)?
What development phase is Etrasimod Immediate Release (IR) in?
What are the side effects of Etrasimod Immediate Release (IR)?
Related
- Manufacturer: Pfizer Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing